Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT02014805
• Date of registration: 07/12/2013
• Prospective Registration: No
• Primary sponsor: Chinese Academy of Medical Sciences
• Public title: Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma
• Scientific title: A Multi-institutional, Randomized Controlled Trial of Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma
• Date of first enrolment: July 2013
• Target sample size: 210
• Recruitment status: Recruiting
• URL: https://clinicaltrials.gov/show/NCT02014805
• Study type: Interventional
• Study design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
• Phase: Phase 3

Countries of recruitment

China

Contacts

• Name: Qinfu Feng, M.D.

• Name: Qinfu Feng, M.D.
• Affiliation: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

• Name: Shuting Li, Ph.D.

Key inclusion & exclusion criteria

Inclusion Criteria:

- Age 18-75, Zubrod-ECOG-WHO 0-2, the interval of surgery to radiotherapy < 2months,
Masaoka stage II-III and WHO B type thymoma

Exclusion Criteria:

- No second primary tumor, no serious comorbidity, no neoadjuvant anticancer treatment,
no adjuvant chemotherapy.



Age minimum: 18 Years
Age maximum: 75 Years
Gender: All

Health Condition(s) or Problem(s) studied

Thymoma

Intervention(s)

Radiation: radiotherapy

Primary Outcome(s)

3 year local control rate [Time Frame: 3 year after the end of all enrollment]

Secondary Outcome(s)

3 year failure-free and overall survival [Time Frame: 3 year after the end of all enrollment]

Secondary ID(s)

POCRT

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

309th Hospital of Chinese People's Liberation Army

Beijing Hospital